Serial No.: 09/668,555

1. (Three times amended) A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting essentially of:

first molecules directed against CD3, and
second molecules, distinct from said first molecules, said second molecules directed against
CD7, wherein at least one of said first and said second molecules include a toxic moiety and
wherein said pharmaceutical composition contains no antibodies other than those antibodies
that bind CD3 and those antibodies that bind CD7.

- 2. (Twice Amended) The method according to claim 15, wherein said second molecules specifically recognize CD7.
- 3. (Twice Amended) The pharmaceutical composition of claim 1, wherein said first molecules are antibodies.
- 4. (Twice Amended) The pharmaceutical composition of claim 1, wherein said second molecules are antibodies.
- 7. (Twice Amended) The pharmaceutical composition of claim 1, wherein said toxic moiety is chemically linked to said first and/or second molecules.
- 8. (Twice Amended) The pharmaceutical composition of claim 1, wherein said first and second molecules are provided with toxic moieties, which may be the same or different toxic moieties.
- 10. (Twice Amended) The pharmaceutical composition of claim 1, wherein said first molecules are gamma2B IgG.

Serial No.: 09/668,555

11. (Twice Amended) The pharmaceutical composition of claim 5, wherein the toxic moiety is at least the equivalent dose of 25 micrograms of ricin A per square meter of body surface of a subject to which the composition is to be administered.

- 12. (Twice Amended) The pharmaceutical composition of claim 11, wherein the toxic moiety is at least the equivalent dose of 100 micrograms of ricin A per square meter of the subject's body surface per administration.
- 13. (Twice Amended) The pharmaceutical composition of claim 11, wherein the toxic moiety is at most the equivalent dose of 25 mg of ricin A per square meter of the subject's body surface per infusion.
- 15. (Three times Amended) A method of treating a disease state in a subject believed to be suffering therefrom, said disease state comprising at least one of Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune disease, said method comprising administering to the subject an amount of a pharmaceutical composition consisting essentially of:

first molecules directed against a CD3 positive cell, and second molecules, distinct from said first molecules, directed against a CD7 positive cell, wherein at least the second molecules include a toxic moiety and wherein said pharmaceutical composition contains no antibodies other than those antibodies that bind CD3 and those antibodies that bind CD7.

- 18. (Amended) The pharmaceutical composition of claim 2, wherein said first molecules are antibodies.
- 19. (Amended) The pharmaceutical composition of claim 18, wherein said second molecules are antibodies.

Serial No.: 09/668,555

21. (Amended) The pharmaceutical composition of claim 19, wherein said toxic moiety is chemically linked to said first and second molecules.

- 22. (Amended) The pharmaceutical composition of claim 21, wherein both said first and second molecules are provided with toxic moieties, which may be the same or different toxic moieties.
- 23. (Amended) The pharmaceutical composition of claim 18, wherein said first molecules are gamma2B IgG.
- 24. (Amended) A pharmaceutical composition for eliminating or reducing the number of unwanted CD3 and/or CD7 positive cells, said pharmaceutical composition consisting of:

anti-CD3 antibodies; and

anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.

25. (Amended) A method of treating a disease state in a subject believed to be suffering therefrom, said disease state comprising at least one of Graft vs. Host disease, graft rejections, T-cell leukemias, T-cell lymphomas, other lymphomas, other CD3 and/or CD7 malignancies, autoimmune diseases, and infectious immune diseases, said method comprising administering to the subject an amount of a pharmaceutical composition consisting of:

anti-CD3 antibodies; and

anti-CD7 antibodies, wherein each of said anti-CD3 antibodies and said anti-CD7 antibodies include a toxic moiety.

26. The composition of claim 1, wherein said second molecules include a toxic moiety.